Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Current Deferred Revenue (2016 - 2025)

Traws Pharma (TRAW) has disclosed Current Deferred Revenue for 14 consecutive years, with $226000.0 as the latest value for Q1 2025.

  • For Q1 2025, Current Deferred Revenue changed 0.0% year-over-year to $226000.0; the TTM value through Mar 2025 reached $226000.0, changed 0.0%, while the annual FY2024 figure was $226000.0, 0.0% changed from the prior year.
  • Current Deferred Revenue hit $226000.0 in Q1 2025 for Traws Pharma, roughly flat from $226000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $227000.0 in Q2 2024 and bottomed at $226000.0 in Q1 2021.
  • Average Current Deferred Revenue over 5 years is $226058.8, with a median of $226000.0 recorded in 2021.
  • Year-over-year, Current Deferred Revenue changed 0.0% in 2021 and then increased 0.44% in 2024.
  • Traws Pharma's Current Deferred Revenue stood at $226000.0 in 2021, then changed by 0.0% to $226000.0 in 2022, then changed by 0.0% to $226000.0 in 2023, then changed by 0.0% to $226000.0 in 2024, then changed by 0.0% to $226000.0 in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $226000.0, $226000.0, and $226000.0 for Q1 2025, Q4 2024, and Q3 2024 respectively.